Welcome Dr. Martin Ingelsson

We would like to welcome Dr. Martin Ingelsson (Professor, Department of Medicine, University of Toronto), to the CPIN Program. Dr. Ingelsson earned his MD in 1995 and his PhD in 2001, both from the Karolinska Institute in Stockholm. From 2001 to 2004, he completed a three-year postdoctoral fellowship at Massachusetts General Hospital, where he later returned for a sabbatical year in 2014–2015. He served as Professor of Geriatrics at Uppsala University from 2016 to 2021. Since 2021, he has been a Professor of Medicine at the University of Toronto and a Clinician Scientist at the University Health Network/Toronto Western Hospital. The aim of Dr. Ingelsson’s research is to increase understanding of the neurotoxic mechanisms involved in Alzheimer’s disease and Parkinson’s disease and to apply this knowledge to the development of novel diagnostic and therapeutic approaches for these disorders. His research primarily evaluates immunotherapy and gene therapy strategies targeting pathogenic protein species using cell and animal models of the respective diseases. Among other achievements, a monoclonal anti-alpha-synuclein antibody developed by his research group in collaboration with BioArctic AB is currently being evaluated in a Phase IIa clinical trial for Parkinson’s disease. Dr. Ingelsson has published close to 250 research papers, reviews, and book chapters and has an H-index of 83. He has supervised 19 PhD students, including six as the primary supervisor and thirteen as a co-supervisor, with one student currently ongoing. He has also supervised 11 postdoctoral fellows as the primary supervisor, three of whom are currently ongoing.